|
1.
|
|
10 p, 903.6 KB |
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
/
Perl, Alexander E. (University of Pennsylvania) ;
Larson, Richard A (University of Chicago) ;
Podoltsev, Nikolai A. (Yale School of Medicine) ;
Strickland, Stephen (Vanderbilt-Ingram Cancer Center) ;
Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ;
Atallah, Ehab (Medical College of Wisconsin) ;
Schiller, Gary J. (David Geffen School of Medicine at UCLA) ;
Martinelli, Giovanni (IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST S.r.l) ;
Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Recher, Christian (Centre Hospitalier Universitaire de Toulouse. Institut Universitaire du Cancer de Toulouse Oncopole. Université de Toulouse 3 Paul Sabatier) ;
Yoon, Sung-Soo (Seoul National University Hospital) ;
Maeda, Yoshinobu (Okayama University Hospital) ;
Hosono, Naoko (University of Fukui) ;
Onozawa, Masahiro (Hokkaido University) ;
Kato, Takayrasu (Department of Hematology. University of Tsukuba) ;
Kim, Hee-Je (Catholic Hematology Hospital. College of Medicine. The Catholic University of Korea) ;
Hasabou, Nahla (Astellas Pharma US. Inc.) ;
Nuthethi, Rishita (Astellas Pharma US. Inc.) ;
Tiu, Ramon (Astellas Pharma US. Inc.) ;
Levis, Mark J. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University)
The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. [...]
2023 -  10.1016/j.jtct.2022.12.006
Transplantation and Cellular Therapy, Vol. 29 Núm. 4 (april 2023) , p. 265.e1-265.e10
|
|
|
2.
|
|
10 p, 3.0 MB |
Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era
/
Salas, María Queralt (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez Lobato, Luis Gerardo (Hospital Clínic i Provincial de Barcelona) ;
Charry, Paola (Hospital Clínic i Provincial de Barcelona) ;
Suárez-Lledó, Maria (Hospital Clínic i Provincial de Barcelona) ;
Pedraza, Alexandra (Hospital Clínic i Provincial de Barcelona) ;
Solano, María Teresa (Hospital Clínic i Provincial de Barcelona) ;
Arcarons, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lozano, Miquel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Esteve, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernandez Aviles, Francesc (Hospital Clínic i Provincial de Barcelona) ;
Martínez, Carmen (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
We investigated the predictive capacity of six prognostic indices [Karnofsky Performance Status (KPS), Hematopoietic Cell Transplant-Specific Comorbidity Index (HCT-CI), Disease Risk Index (DRI), European Bone Marrow Transplantation (EBMT) and Revised Pre-Transplantation Assessment of Mortality (rPAM) Scores and Endothelial Activation and Stress Index (EASIX)] in 205 adults undergoing post-transplant cyclophosphamide (PTCy)-based allo-HCT. [...]
2023 - 10.1016/j.htct.2023.07.008
Hematology, Transfusion and Cell Therapy, 2023
|
|
|
3.
|
|
16 p, 1.1 MB |
Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications
/
Palomo, Marta (Hospital Clínic i Provincial de Barcelona) ;
Moreno-Castaño, Ana Belén (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Salas, María Queralt (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Escribano-Serrat, Silvia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rovira, Montserrat (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Guillen-Olmos, Elena (Hospital Clínic i Provincial de Barcelona) ;
Fernandez, Sara (Hospital Clínic i Provincial de Barcelona) ;
Ventosa-Capell, Helena (Hospital Clínic i Provincial de Barcelona) ;
Youssef, Lina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Crispi, Fatima (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Nomdedeu, Meritxell (Hospital Clínic i Provincial de Barcelona) ;
Martinez-Sanchez, Julia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
De Moner, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Diaz-Ricart, Maribel (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
The endothelium is a biologically active interface with multiple functions, some of them common throughout the vascular tree, and others that depend on its anatomical location. Endothelial cells are continually exposed to cellular and humoral factors, and to all those elements (biological, chemical, or hemodynamic) that circulate in blood at a certain time. [...]
2023 - 10.3389/fmed.2023.1285898
Frontiers in Medicine, Vol. 10 (2023) , p. 1285898
|
|
|
4.
|
|
3 p, 444.0 KB |
Prevention of veno-occlusive disease/sinusoidal obstruction syndrome : a never-ending story and no easy answer
/
Corbacioglu, Selim (University of Regensburg) ;
Grupp, S.A. (The Children's Hospital of Philadelphia) ;
Richardson, Paul G.. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Duarte, R. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Pagliuca, A. (King's College Hospital and Anthony Nolan Research Institute) ;
Ruutu, T. (Helsinki University Hospital) ;
Mahadeo, K. (Duke University Children's Hospital) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
2023 - 10.1038/s41409-023-02007-2
Bone marrow transplantation, Vol. 58 Núm. 8 (august 2023) , p. 839-841
|
|
|
5.
|
|
6 p, 688.3 KB |
Do Patients and Physicians Agree When They Assess Quality of Life?
/
Barata, Anna (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Gich, Ignasi (Institut d'Investigació Biomèdica Sant Pau) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya)) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Brunet, Salut (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
García-Pallarols, Francesc (Hospital del Mar (Barcelona, Catalunya)) ;
Garrido, Ana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Granell, Miguel (Institut d'Investigació Biomèdica Sant Pau) ;
Martinez, Jaume (Hospital Universitari Vall d'Hebron) ;
Mensa, Irene (Hospital Universitari Vall d'Hebron) ;
Novelli, Silvana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Sánchez-González, Blanca (Hospital del Mar (Barcelona, Catalunya)) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Patient and physician agreement on the most significant symptoms is associated with treatment outcomes and satisfaction with care. Thus, we sought to assess patient and physician agreement on patient-reported quality of life (QoL), and whether patient-related variables predict disagreement. [...]
2017 - 10.1016/j.bbmt.2017.03.015
Biology of blood and marrow transplantation, Vol. 23 Núm. 6 (june 2017) , p. 1005-1010
|
|
|
6.
|
|
9 p, 1.2 MB |
Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia : Clinically Relevant Time Points and 100 Copies Threshold Value
/
Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Carricondo, Maite (Institut d'Investigació Biomèdica Sant Pau) ;
Pratcorona, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Hoyos Colell, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Garrido, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rubio, Miguel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bussaglia, Elena (Institut d'Investigació Biomèdica Sant Pau) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Estivill, Camino (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Brunet, Salut (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
The outcome of allogeneic hematopoietic stem cell transplantation (HCT) in patients with myeloid malignancies is better in those without minimal residual disease (MRD) than in those with MRD+, as assessed by multiparametric flow cytometry (MPFC). [...]
2018 - 10.1016/j.bbmt.2017.09.001
Biology of blood and marrow transplantation, Vol. 24 Núm. 1 (january 2018) , p. 55-63
|
|
|
7.
|
|
25 p, 635.6 KB |
CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome
/
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Qin (Memorial Sloan Kettering Cancer Center) ;
Cho, Christina (Weill Cornell Medical College) ;
Castro-Malaspina, Hugo (Weill Cornell Medical College) ;
Devlin, Sean M (Memorial Sloan Kettering Cancer Center) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Giralt, Sergio (Weill Cornell Medical College) ;
Jakubowski, Ann A. (Weill Cornell Medical College) ;
Caballero, Dolores (Hospital Universitario Salamanca (CAUSA/IBSAL)) ;
Maloy, Molly (Memorial Sloan Kettering Cancer Center) ;
Papadopoulos, Esperanza B. (Weill Cornell Medical College) ;
Piñana, José Luis (Hospital Clínic Universitari (València)) ;
Fox, Maria Laura (Hospital Universitari Vall d'Hebron) ;
Márquez-Malaver, Francisco J. (Hospital Virgen del Rocío Sevilla) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Solano, Carlos (Hospital Clínic Universitari (València)) ;
López-Corral, Lucía (Hospital Universitario Salamanca (CAUSA/IBSAL)) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Perales, Miguel-Angel (Weill Cornell Medical College) ;
Universitat Autònoma de Barcelona
Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34 cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). [...]
2018 - 10.1016/j.bbmt.2017.12.804
Biology of blood and marrow transplantation, Vol. 24 Núm. 5 (may 2018) , p. 964-972
|
|
|
8.
|
|
10 p, 971.5 KB |
Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation
/
Sabloff, Mitchell (University of Ottawa and Ottawa Hospital Research Institute) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Wang, Tao (Medical College of Wisconsin) ;
Fretham, Caitrin (National Marrow Donor Program/Be the Match) ;
Kekre, Natasha (The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute) ;
Abraham, Allistair (Children's National Medical Center) ;
Adekola, Kehinde (Northwestern University) ;
Auletta, Jeffery J. (Nationwide Children's Hospital) ;
Barker, Christopher (Memorial Sloan Kettering Cancer Center) ;
Beitinjaneh, Amer (University of Miami) ;
Bredeson, Christopher (The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute) ;
Cahn, Jean-Yves (CHU Grenoble Alpes) ;
Diaz, Miguel Angel (Hospital Infantil Universitario Niño Jesus) ;
Freytes, Cesar (Texas Transplant Institute) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Health System) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center) ;
Guinan, Eva (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Hashmi, Shahrukh (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Hematti, Peiman (University of Wisconsin) ;
Hildebrandt, Gerhard (University of Kentucky) ;
Holmberg, Leona (Fred Hutchinson Cancer Research Center) ;
Hong, Sanghee (Cleveland Clinic Taussig Cancer Center) ;
Lazarus, Hillard M. (Case Western Reserve University) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Muffly, Lori (Stanford University) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ;
Yared, Jean (University of Maryland) ;
Mineishi, Shin (Penn State Hershey Medical Center) ;
Stadtmauer, Edward A. (University of Pennsylvania Medical Center) ;
Pasquini, Marcelo (Medical College of Wisconsin) ;
Loren, Alison W. (Perelman School of Medicine at the University of Pennsylvania) ;
Universitat Autònoma de Barcelona
Malignancy relapse is the most common cause of treatment failure among recipients of hematopoietic cell transplantation (HCT). Conditioning dose intensity can reduce disease relapse but is offset by toxicities. [...]
2019 - 10.1016/j.bbmt.2019.08.012
Biology of blood and marrow transplantation, Vol. 25 Núm. 12 (december 2019) , p. 2398-2407
|
|
|
9.
|
|
9 p, 534.4 KB |
Rapid and accurate method for quantifying busulfan in plasma samples by isocratic liquid chromatography-tandem mass spectrometry (LC-MS/MS)
/
Villena-Ortiz, Yolanda (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Castellote-Bellés, Laura (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez Sánchez, Luisa María (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Benítez-Carabante, María I. (Vall d'Hebron Institut de Recerca. Departament d'Hematologia i Oncologia Pediàtrica) ;
Miarons, Marta (Vall d'Hebron Institut de Recerca. Departament de Farmàcia) ;
Vima-Bofarull, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Barquin-DelPino, Raquel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Paciucci, Rosanna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rodríguez Frías, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Ferrer-Costa, Roser (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Casis-Saez, Ernesto (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
López-Hellín, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Objectives: Administration of busulfan is extending rapidly as a part of a conditioning regimen in patients undergoing hematopoietic stem cell transplantation (HSCT). Monitoring blood plasma levels of busulfan is recommended for identifying the optimal dose in patients and for minimizing toxicity. [...]
2022 - 10.1515/almed-2022-0016
Advances in Laboratory Medicine, Vol. 3, Issue 3 (September 2022) , p. 263-271
|
|
|
10.
|
|
8 p, 316.8 KB |
Solid organ transplantation after hematopoietic stem cell transplantation in childhood : A multicentric retrospective survey
/
Faraci, Maura (Istituto G Gaslini) ;
Bertaina, Alice (Stanford University) ;
Dalissier, Arnaud (European Society for Blood and Marrow Transplantation Pediatric Disease Working Party) ;
Ifversen, Marianne (Copenhagen University Hospital) ;
Schulz, Ansgar (University Medical Center) ;
Gennery, Andrew (Great North Children's Hospital) ;
Burkhardt, Birgit (University Hospital of Münster (Alemanya)) ;
Badell Serra, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Díaz de Heredia, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Lanino, Edoardo (Istituto G Gaslini) ;
Lankester, Arjan C. (Leiden University Medical Center) ;
Gruhn, Bernd (Jena University Hospital (Alemania)) ;
Matthes-Martin, Susanne Medical University of Vienna ;
Kühl, Joern S. (Universitätsklinikum Leipzig) ;
Varotto, Stefania (University Hospital of Padova (Pàdua, Itàlia)) ;
Paillard, Catherine (Hôpital Hautepierre) ;
Guilmatre, Audrey (Hôpital Armand Trousseau (París, França)) ;
Sastre, Ana (Hospital Universitario La Paz (Madrid)) ;
Abecasis, Manuel (Instute Portugues Oncologia Lisboa) ;
Garwer, Birgit (University Hospital Eppendorf) ;
Sedlacek, Petr (University Hospital Motol) ;
Boelens, Jaap Jan (Memorial Sloan Kettering Cancer Center) ;
Beohou, Eric (European Society for Blood and Marrow Transplantation Pediatric Disease Working Party) ;
Bader, Peter (University Hospital of Frankfurt (Alemanya)) ;
Universitat Autònoma de Barcelona
We report data obtained from a retrospective multicenter pediatric survey on behalf of the European Society for Blood and Marrow Transplantation (EBMT). Information on solid organ transplantation (SOT) performed in pediatric recipients of either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 was collected in 20 pediatric EBMT Centers (25. [...]
2019 - 10.1111/ajt.15240
American Journal of Transplantation, Vol. 19 Núm. 6 (june 2019) , p. 1798-1805
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
